Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fsabcs-2021%2Fnivolumab-plus-ipilimumab-serve-promising-dual-checkpoint-inhibition%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CBreast+Cancer%7CPhase+1%E2%80%933+Trials%7CSABCS+2021%7COncology&conference=SABCS+2021): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Nivolumab plus ipilimumab serve promising dual checkpoint inhibition - Medical Conferences

Home > Oncology > SABCS 2021 > Phase 1–3 Trials > Nivolumab plus ipilimumab serve promising dual checkpoint inhibition

Nivolumab plus ipilimumab serve promising dual checkpoint inhibition

Presented By
Dr Romualdo Barroso-Sousa , Hospital Sírio-Libanês, Brazil

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 2, NIMBUS

Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for patients with HER2-negative metastatic breast cancer and high tumour mutational burden (TMB).

In the open-label, multicentre, phase 2 NIMBUS trial (NCT03789110), the efficacy and safety of dual checkpoint inhibition with nivolumab plus low-dose ipilimumab was evaluated in patients with hyper-mutated breast cancer with a TMB≥9 mutations/megabase (mut/Mb). Dr Romualdo Barroso-Sousa (Hospital Sírio-Libanês, Brazil) presented the results [1].

The NIMBUS study included 30 patients with HER2-negative metastatic breast cancer (70% HR-positive, 30% triple-negative breast cancer) and a TMB of at least 9 mut/Mb (median 10.9 mut/Mb). The median number of prior chemotherapy lines was 1.5 and the maximum was 3. Patients received nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) until disease progression, unacceptable toxicity, or up to 24 months.

During a median 9.7 months of follow-up, there were 5 (16.7%) confirmed objective responses, all of which were partial. A further 6 (20%) patients had stable disease during follow-up. Median duration of response was 12.1 months, while median progression-free survival and overall survival were a respective 1.4 and 19.3 months. Exploratory analyses revealed that in patients with a high TMB (≥14 mut/Mb) the overall response rate was 60% versus 8% in the 25 patients with a TMB of 9–13 mut/Mb. Median progression-free survival and median overall survival was 9.5 months and not reached in patients with a TMB≥14 mut/Mb versus 1.4 months and 8.8 months in patients with a TMB of 9–13 mut/Mb.

Based on these results, Dr Barrosso-Sousa concluded that: “this study supports the use of checkpoint inhibitors among patients with HER2-negative metastatic breast cancer and TMB. However, the study does not answer the question whether dual checkpoint inhibition is better than pembrolizumab monotherapy.”

  1. Barroso-Sousa R, et al. Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). GS2-10, SABCS 2021 Virtual Meeting, 7–10 December.

Copyright ©2022 Medicom Medical Publishers



Posted on